{"id":45554,"date":"2022-06-27T19:01:45","date_gmt":"2022-06-27T17:01:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/"},"modified":"2022-06-27T19:01:45","modified_gmt":"2022-06-27T17:01:45","slug":"kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/","title":{"rendered":"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment"},"content":{"rendered":"
\n

INDIANAPOLIS–(BUSINESS WIRE)–Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute\/NIH. With successful achievement of its milestones, the award will transition to a Small Business Innovation Research (SBIR) award and will provide approximately $2,400,000 over three years.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are excited to receive NCI funding to support Kovina\u2019s development of therapeutic treatments for Human Papillomavirus (HPV) related cancers,\u201d said Kristin Sherman, CEO of Kovina Therapeutics. \u201cHPV causes nearly all cervical and many oropharyngeal, anal, and genital cancers. Kovina is focused on developing expanded treatment options for patients afflicted with these malignancies.\u201d\n<\/p>\n

\n\u201cWe are pleased Kovina\u2019s research proposal successfully competed in NCI\u2019s rigorous merit-based review process,\u201d said Dr. Elliot Androphy, CSO of Kovina Therapeutics. Kovina\u2019s technology specifically targets a key HPV protein expressed in early, pre-malignant and cancerous pathologies. By inactivating this protein, Kovina\u2019s compounds result in the selective death of HPV infected cells. \u201cOur therapeutics are designed to stop HPV infections before cancer develops and to treat HPV related cancers after detection.\u201d\n<\/p>\n

\nAbout Kovina Therapeutics<\/b>\n<\/p>\n

\nKovina Therapeutics is a biotechnology company developing first-in-class antiviral therapies to treat cancers and pre-malignant infections caused by Human Papillomavirus (HPV). Kovina has assembled a team of scientists and industry leaders with expertise in HPV and small molecule drug design to advance its pipeline of drug candidates. To learn more, visit www.Kovina.com<\/a>.\n<\/p>\n

\nAbout NCI SBIR<\/b>\n<\/p>\n

\nThe SBIR\/STTR program https:\/\/sbir.cancer.gov<\/a> is one of the nation\u2019s largest sources of financing for technology innovation. The National Cancer Institute\u2019s SBIR Development Center provides funding, mentoring, and networking assistance to small businesses developing innovative cancer technologies, with the ultimate goal of bringing innovation from the lab to patients.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKristin Sherman
\n
CEO, Kovina Therapeutics Inc.
\n
317-224-9736
\n
Kristin.Sherman@kovina.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

INDIANAPOLIS–(BUSINESS WIRE)–Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute\/NIH. With successful achievement of its milestones, the award will transition to a Small Business Innovation Research (SBIR) award and will provide approximately $2,400,000 over three years. \u201cWe are excited to receive NCI funding to support … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45554","6":"format-standard","7":"category-industry"},"yoast_head":"\nKovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"INDIANAPOLIS–(BUSINESS WIRE)–Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute\/NIH. With successful achievement of its milestones, the award will transition to a Small Business Innovation Research (SBIR) award and will provide approximately $2,400,000 over three years. \u201cWe are excited to receive NCI funding to support ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-27T17:01:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220627005610\/en\/1497922\/21\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment\",\"datePublished\":\"2022-06-27T17:01:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/\"},\"wordCount\":317,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220627005610\\\/en\\\/1497922\\\/21\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/\",\"name\":\"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220627005610\\\/en\\\/1497922\\\/21\\\/Logo.jpg\",\"datePublished\":\"2022-06-27T17:01:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220627005610\\\/en\\\/1497922\\\/21\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220627005610\\\/en\\\/1497922\\\/21\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment - Pharma Trend","og_description":"INDIANAPOLIS–(BUSINESS WIRE)–Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute\/NIH. With successful achievement of its milestones, the award will transition to a Small Business Innovation Research (SBIR) award and will provide approximately $2,400,000 over three years. \u201cWe are excited to receive NCI funding to support ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-27T17:01:45+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220627005610\/en\/1497922\/21\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment","datePublished":"2022-06-27T17:01:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/"},"wordCount":317,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220627005610\/en\/1497922\/21\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/","url":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/","name":"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220627005610\/en\/1497922\/21\/Logo.jpg","datePublished":"2022-06-27T17:01:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220627005610\/en\/1497922\/21\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220627005610\/en\/1497922\/21\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-national-cancer-institute-grant-to-advance-human-papillomavirus-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45554"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45554\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}